| Literature DB >> 25460346 |
Daniel H Libraty1, Lei Zhang2, AnaMae Obcena3, Job D Brion4, Rosario Z Capeding5.
Abstract
Dengue is the most prevalent arthropod-borne viral illness in humans. The current gold standard serologic test for dengue virus (DENV) infection is a neutralizing antibody assay. We examined a DENV recombinant (r)E protein domain III IgG ELISA among infants with primary DENV infections. Infants experience a primary DENV infection in the presence of maternally derived anti-DENV IgG. The estimated DENV rE protein domain III IgG levels to the infecting serotype at the time of infant primary symptomatic DENV2 and DENV3 infections correlated with the 50% plaque reduction neutralization reciprocal antibody titers (PRNT50). Anti-DENVs 1-4 rE protein domain III IgG levels all correlated with each other, and the estimated rE protein domain III IgG level to the infecting serotype at the time of infection inversely correlated with dengue disease severity. The anti-DENV rE protein domain III IgG ELISA may be a useful and potentially high-throughput alternative to traditional DENV neutralizing antibody assays.Entities:
Keywords: Dengue; ELISA; Envelope protein; Serologic assay
Mesh：
Substances：
Year: 2014 PMID： 25460346 PMCID： PMC4277722 DOI： 10.1016/j.actatropica.2014.11.009
Source DB: PubMed Journal: Acta Trop ISSN： 0001-706X Impact factor: 3.112